SEC filing record
Primary Source · SEC.gov

GEN1E LIFESCIENCES INC.

2025 vintageRule 506(b)Filing record

Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form D; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.

Latest signalNew Form D filerForm D · 2025-12-29Last filing 2025-12-29

Raised

$6M

Investors

44

Min Invest

None stated

AltStreet Verified Issuer badge

Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.

What this filing shows

·

Every sentence is a value as filed on SEC Form D

GEN1E LIFESCIENCES INC. is a Delaware corporation that filed a Form D with the SEC on December 29, 2025 in the Biotechnology industry group. The offering claims Rule 506(b) and covers equity. GEN1E LIFESCIENCES INC. reported $5,520,803 sold from 44 investors of a $11,887,377 total offering as of the Form D filed December 29, 2025. The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated. The Form D names no recipient of sales compensation, which usually means the issuer or its affiliates are placing the securities directly. Sales commissions are reported as $0 and finders' fees as $0. Form D allows these to be estimates. The issuer's address of record is 1123 Stanford Ave, Palo Alto, CA 94306.

EDGAR Filing Data

Form D — Primary Source

View on SEC.gov
CIK Number0001752886
Entity NameGEN1E LIFESCIENCES INC.
ExemptionRule 506(b)
What the exemption meansRule 506(b) of Regulation D: securities may be sold to an unlimited number of accredited investors and up to 35 non-accredited investors who meet the rule's sophistication standard, without general solicitation or advertising.
Entity TypeCorporation
Jurisdiction of OrganizationDelaware
Issuer Address1123 Stanford Ave, Palo Alto, CA 94306
Phone(408) 813-6283
Industry / Fund TypeBiotechnology
Securities TypeEquity
First Sale DateOctober 21, 2025
Filing DateDecember 29, 2025
Accession Number0001752886-25-000002
Total Offering Amount$11,887,377
Total Amount Sold$5,520,803
Amount Remaining$6,366,574
Total Investors44
Non-Accredited InvestorsNone
Minimum Investment$0 (no stated minimum)
Offering DurationOne year or less
Sales Commissions$0
Finders' Fees$0
Revenue RangeDecline to Disclose
State (Issuer Address)CA
Amendment Count2 filings on record

Filings on Record

Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.

In the Terminal

Filing events

1

latest Dec 29, 2025

Critical / warning

0 / 0

0 watch · 1 info

Statements extracted

0

none on file

NAV prints

0

none on file

Offering chains

2

lapsed, raising

Latest event New filer · Dec 29, 2025

SEC.gov
Open in the terminal Watch this issuerInvestor $149/mo unlocks the values; Pro $349/mo adds the universe.

Investor

  • 1 filing event with values and deltas, latest 2025-12-29, and alerts on the next one
  • 2 offering timelines: velocity, share raised, first-sale lag, stalled flags

Pro

  • This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
  • The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV

Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…

Related Persons (Form D)

Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.

Item 3 changed on the Form D filed 2025-12-29: 1 related person added and 0 removed against the filing of 2022-12-21; 5 now listed. The names are in the Terminal feed.

Soujanya Bhumkar

Executive Officer, Director · Palo Alto, CA

Noor Kamruddin

Director · Palo Alto, CA

Ritu Lal

Executive Officer, Director · Palo Alto, CA

Alan Levy

Director · Palo Alto, CA

Francois Nader

Director · Palo Alto, CA

Questions About GEN1E LIFESCIENCES INC.

Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.

What is GEN1E LIFESCIENCES INC.?

GEN1E LIFESCIENCES INC. is a Delaware corporation that filed a Form D with the SEC on December 29, 2025 in the Biotechnology industry group. The filing claims Rule 506(b) for an offering of equity.

Is GEN1E LIFESCIENCES INC. legit?

AltStreet does not rate legitimacy; it reports the public record. GEN1E LIFESCIENCES INC. filed a Form D with the SEC on December 29, 2025 claiming Rule 506(b). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $5,520,803 sold to 44 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.

Is GEN1E LIFESCIENCES INC. registered with or approved by the SEC?

No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that GEN1E LIFESCIENCES INC. claimed Rule 506(b) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.

How much has GEN1E LIFESCIENCES INC. raised?

GEN1E LIFESCIENCES INC. reported $5,520,803 sold from 44 investors of a $11,887,377 total offering as of the Form D filed December 29, 2025.

Who can invest in GEN1E LIFESCIENCES INC.?

The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated.

What is the minimum investment in GEN1E LIFESCIENCES INC.?

The Form D lists the minimum investment as $0, which means the issuer did not state a minimum on the form. The offering documents, not the Form D, set the actual subscription terms.

Who is selling GEN1E LIFESCIENCES INC. and how are they paid?

The Form D names no recipient of sales compensation, which usually means the issuer or its affiliates are placing the securities directly. Sales commissions are reported as $0 and finders' fees as $0. Form D allows these to be estimates.

Who is behind GEN1E LIFESCIENCES INC.?

The Form D lists 5 related persons: Soujanya Bhumkar, executive officer, director; Noor Kamruddin, director; Ritu Lal, executive officer, director; Alan Levy, director; Francois Nader, director. Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.

Where is GEN1E LIFESCIENCES INC. located?

The issuer's address on its SEC filings is 1123 Stanford Ave, Palo Alto, CA 94306. Its phone number of record is 4088136283. It is organized under the laws of Delaware.

How long is the GEN1E LIFESCIENCES INC. offering open?

The issuer indicated that the offering is not intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open, and no amendment is on record yet.

What is GEN1E LIFESCIENCES INC.'s revenue?

The issuer declined to disclose its revenue range on the Form D, which the form permits.

AltStreet Verified Issuer badge

Is this your company or fund?

Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.

Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.

Data Methodology

Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.